Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 25, 2024HaematologicaOpen Access

A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: Stage 2 of a phase II trial

View Full Paper
Ask AI
Bookmark
Share

Authors

SVSrđan VerstovšekMTMoshe TalpazMWMartha Wadleigh

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Verstovšek et al. (2024) studied this question.

synapsesocial.com/papers/6a8166f4ada1eccddc33bc13https://doi.org/10.3324/haematol.2023.284410
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Patient characteristics and outcomes after ruxolitinib discontinuation in patients with myelofibrosis2020 · 56 citations
  2. 2Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia2017 · 44 citations
  3. 3Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis2022 · 67 citations
  4. 4Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial2023 · 17 citations